

Special Issue

Innovative and Translational Antibiosis Approaches to Tackling Protozoan Parasites: Synergy, Drug Repurposing, Natural Products, Molecular Targets, and Therapeutic Design

Message from the Guest Editor

Protozoan neglected diseases, such as leishmaniasis, Chagas disease, African trypanosomiasis, amebiasis, and giardiasis, remain a major global health challenge. A critical limitation in current therapies is the increasing resistance of protozoan parasites to available drugs, together with frequent therapeutic failures, reflecting the global challenge of antimicrobial resistance. Therefore, this Special Issue will highlight strategies that directly address antiparasitic drug resistance, advancing the wider efforts against antimicrobial resistance but in the specific context of protozoan pathogens. This Special Issue will focus on novel therapeutic approaches to tackling protozoan parasites, emphasizing synergistic drug combinations, the repurposing of clinically approved compounds, natural products with antiparasitic activity, and the rational design of new chemical entities. By integrating drug repurposing, natural compound discovery, synergistic strategies, microbial therapies, and therapeutic design, this Special Issue will provide a comprehensive platform for advancing antibiosis research and developing safer, more effective treatments against protozoan neglected diseases.

Guest Editor

Dr. Leonardo Acuña
Instituto de Patología Experimental, Salta, Argentina

Deadline for manuscript submissions

30 May 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/253077

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)